The real revolution came in 2012, when researchers Jennifer Doudna and Emmanuelle Charpentier harnessed CRISPR, a natural bacterial defense system. In bacteria, CRISPR cuts out invading viruses’ DNA ...

Promising results from a small clinical trial highlight a growing interest in designing gene-editing treatments for common ...

An experimental gene-editing treatment shows promise for permanently lowering levels of cholesterol and triglycerides, ...

An experimental gene-editing therapy developed by Crispr Therapeutics is showing promise for treating heart disease.

Crispr stock reversed lower Monday, while Intellia stock surged, on promising updates for their gene-editing efforts.

By reactivating a long-lost gene, researchers were able to lower uric acid levels and stop damaging fat accumulation in human ...

The approach is “very exciting,” but one expert says a lot more research is needed, especially around safety, before clinical ...

Explore CRISPR technology explained, gene editing science, DNA modification, and genetic engineering ethics—discover how ...

CRISPR Therapeutics' CTX310 trial shows strong, sustained lipid reductions and favorable safety, boosting confidence in its ...

CRISPR Therapeutics AG is rated a Buy with $1.9B cash, prudent management, and undervalued shares. Learn more about CRSP ...

According to the 13F filing with the Securities and Exchange Commission dated Nov. 12, 2025, ARK Investment Management sold ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...